See more : Sky Gold Corp. (SRKZF) Income Statement Analysis – Financial Results
Complete financial analysis of Stealth BioTherapeutics Corp (MITO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Stealth BioTherapeutics Corp, a leading company in the Biotechnology industry within the Healthcare sector.
- Acquired Sales Corp. (AQSP) Income Statement Analysis – Financial Results
- Wirecard AG (WDI.SW) Income Statement Analysis – Financial Results
- First Keystone Corporation (FKYS) Income Statement Analysis – Financial Results
- Shemaroo Entertainment Limited (SHEMAROO.BO) Income Statement Analysis – Financial Results
- Biotest Aktiengesellschaft (BTTAY) Income Statement Analysis – Financial Results
Stealth BioTherapeutics Corp (MITO)
About Stealth BioTherapeutics Corp
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 21.09M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.56M | 29.31M | 44.60M | 53.06M | 63.22M | 48.45M |
| General & Administrative | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.75M | 19.37M | 22.32M | 22.22M | 16.50M | 13.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Cost & Expenses | 46.30M | 48.67M | 66.92M | 75.28M | 79.72M | 61.85M |
| Interest Income | 3.00K | 139.00K | 988.00K | 195.09K | 56.84K | 799.02K |
| Interest Expense | 1.24M | 1.81M | 6.67M | 21.36M | 3.28M | 0.00 |
| Depreciation & Amortization | 77.00K | 232.00K | 284.00K | 309.04K | 346.87K | 312.54K |
| EBITDA | -51.21M | -55.42M | -64.78M | -75.05M | -79.28M | -60.74M |
| EBITDA Ratio | 0.00% | 0.00% | -307.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -51.29M | -48.67M | -45.83M | -75.28M | -79.72M | -61.85M |
| Operating Income Ratio | 0.00% | 0.00% | -217.35% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.22M | -8.79M | -25.90M | -21.43M | -3.19M | 799.02K |
| Income Before Tax | -52.53M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.24M | -6.98M | -19.23M | -76.21K | 92.30K | 799.02K |
| Net Income | -53.77M | -57.46M | -71.73M | -96.71M | -82.91M | -61.05M |
| Net Income Ratio | 0.00% | 0.00% | -340.15% | 0.00% | 0.00% | 0.00% |
| EPS | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| EPS Diluted | -1.16 | -1.24 | -2.29 | -2.93 | -5.22 | -2.99 |
| Weighted Avg Shares Out | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
| Weighted Avg Shares Out (Dil) | 46.35M | 46.35M | 31.31M | 33.02M | 15.88M | 20.38M |
If You Had Bought Stealth BioTherapeutics (NASDAQ:MITO) Stock A Year Ago, You’d Be Sitting On A 91% Loss, Today
Nomura Lowers Stealth BioTherapeutics (NASDAQ:MITO) Price Target to $10.00
Jefferies Financial Group Weighs in on Stealth BioTherapeutics Corp's Q3 2020 Earnings (NASDAQ:MITO)
Stealth BioTherapeutics Corp Expected to Post Q1 2020 Earnings of ($0.03) Per Share (NASDAQ:MITO)
Stealth BioTherapeutics (NASDAQ:MITO) Raised to "Buy" at Zacks Investment Research
Stealth BioTherapeutics (NASDAQ:MITO) Stock Price Up 7.3% Following Analyst Upgrade
Stealth BioTherapeutics Corp (MITO) Q4 2019 Earnings Call Transcript
Stealth BioTherapeutics Corp. to Host Earnings Call
Stealth BioTherapeutics Corp (NASDAQ:MITO) Given Average Recommendation of "Hold" by Brokerages
Source: https://incomestatements.info
Category: Stock Reports